GO
Loading...

Schering-Plough Gets EU Approval for Hepatitis C Treatment

Drug maker Schering-Plough said Monday it received expanded European approval for a combination therapy of Pegintron and Rebetol to treat hepatitis C patients who are also infected with HIV.

The combination therapy was originally approved in Europe in March 2001 for the treatment of hepatitis C alone. Both drugs are made by Schering-Plough .

The latest approval was based on two clinical studies showing that hepatitis C patients, with HIV, who were given Pegintron and Rebetol had significantly lower amounts of the hepatitis C virus six months after treatment compared with those patients given conventional interferon alfa-2b and ribavirin.

The company said about 40 percent of the 2.5 million people living in Europe with HIV were also infected with chronic hepatitis C.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Debating the plan to prevent tax inversions, Doug Holtz-Eakin, American Action Forum, says the Treasurys plan is worse than doing nothing. Christian Weller, Center for American Progress, explains why he favors inversion regulation.

  • CNBC's Eamon Javers discusses the Treasury Department's new rules to discourage companies from moving their headquarters overseas to avoid taxes.

  • Are Treasurys seeing a safe haven bid? CNBC's Rick Santelli and Bob Pisani break down the current action in bonds and equities.